Allergy to peanuts is appearing earlier in the pediatric population.
A review of the medical charts of peanut-allergic patients seen in an academic allergy clinic between 2000 and 2006 showed that the median ages of first peanut exposure and reaction were 14 and 18 months, respectively. In 1995 the median age was 22 months, and in 1997 the median age was 24 months in a similar population in another such clinic. (Green TD et al: Pediatrics 2007;120:1304).
Toxicity related to THC dose in pediatric edible cannabis ingestions
October 3rd 2023The degree of toxicity following pediatric ingestion of THC was correlated to the dose of THC, as ingestions of 1.7 mg/kg or more was predictive of severe and prolonged toxicity, according to a study published in Pediatrics.
FDA approves tocilizumab-bavi as biosimilar for PJIA, SJIA in children 2 years and up
October 2nd 2023Tocilizumab-bavi (Tofidence; Biogen) demonstrated a biosimilarity to tocilizumab (Actemra; Genentech) based on multifaceted clinical and non-clinical data for polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (sJIA) in children aged 2 years and up. This makes it the first tocilizumab biosimilar to be FDA-approved in the United States, according to Biogen.
2 Clarke Drive
Cranbury, NJ 08512